Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: PFE.NYSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Pfizer (PFE) Stock Forecast and AI Rating

Original pricing snapshot Sep 18 2026Deep analysis published Sep 21 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

$29

+5.4%+9.7% incl. dividends

2031

5-Year

BUY

$38

+38.2%+68.2% incl. dividends

Published batch insight

Patent Expiration Abyss Meets Oncology Bridge as Operational Restructuring Defends Cash Flow

High consensus confirms foundational revenue faces significant patent expiration friction through 2028, offset by commercial antibody-drug conjugate momentum and structural cost rationalization. Crucially, underlying free cash flow stabilizes near eleven billion dollars, insulating the high-yield dividend despite heavy acquisition debt obligations.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Superintelligence (Anthropologist), Universal Investor (Polymath), J.P. Morgan (Titan), Machiavelli (Insider), Warren Buffett (Value Purist), Ray Dalio (Strategist), Elon Musk (Visionary), Sherlock Holmes (Whistleblower), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Pfizer at the forecast anchor (2026-09-18): $16,816 in five years versus $13,892 for S&P 500 benchmark.

Pfizer · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 4.0% net dividend yield for Pfizer.

Figure: Five-year synthesized consensus value path for Pfizer compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 27.66 USD1-year price return: +5.44%5-year price return: +38.21%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	28.06	+1.45%	+1.45%	Seasonal respiratory vaccine distributions alongside initial operational restructuring savings stabilize margins. Defensive institutional capital rotates into high-yielding healthcare equities, supporting modest multiple expansion despite restrictive central bank benchmark borrowing rates.
Q1 2027	28.45	+1.37%	+2.84%	Full-year results separate non-cash impairment charges from recurring operating cash flows, reaffirming dividend coverage. Steady volume gains in acquired oncology antibody-drug conjugates counterbalance early international generic pricing pressures.
Q2 2027	28.71	+0.93%	+3.80%	Initial statutory Medicare price adjustments introduce mild top-line friction, but accelerating manufacturing cost-realization milestones protect underlying operating profitability. Commercial oncology momentum preserves balanced, low-volatility price performance.
Q3 2027	29.16	+1.58%	+5.44%	Pivotal oncology clinical readouts and positive cash-tax sunset relief reinforce operating cash flow. Reinvestment into Phase 3 metabolic trials absorbs capital, keeping quarterly equity valuation gains disciplined and measured.
Q4 2027	29.16	0.00%	+5.44%	Investor apprehension intensifies ahead of impending 2028 major patent expirations, inducing slight valuation compression. Year-end portfolio rebalancing and elevated debt refinancing costs partially offset ongoing administrative cost-reduction benefits.
Q1 2028	28.83	-1.15%	+4.22%	Early generic erosion against core cardiovascular blockbusters arrives, initiating headline top-line contraction. While quarterly free cash flow remains sufficient to service debt, market participants aggressively discount near-term replacement uncertainty.
Q2 2028	28.38	-1.57%	+2.59%	Peak patent-cliff anxiety compresses reported gross margins as generic small-molecule alternatives expand distribution. Free cash flow dividend coverage narrows, though verified run-rate operational savings prevent severe enterprise impairment.
Q3 2028	28.87	+1.75%	+4.38%	Pivotal Phase 3 metabolic data updates and expanding oncology combination indications provide vital clinical validation. Operating margin stabilization confirms that multi-year restructuring programs are effectively cushioning legacy revenue attrition.
Q4 2028	29.63	+2.63%	+7.13%	Commercial oncology volume expansion demonstrates durable standard-of-care market share gains. Management achieves significant debt retirement milestones, prompting contrarian value accumulation as the steepest phase of generic drag clears.
Q1 2029	30.46	+2.80%	+10.13%	Annual financial reporting confirms the structural trough in earnings power has passed. Oncology and rare-disease product growth begins outpacing residual patent erosion, prompting upward revisions in forward cash-flow estimates.
Q2 2029	31.24	+2.56%	+12.95%	Anticipation of regulatory filings for next-generation metabolic and oncology therapies expands institutional valuation multiples. Easing interest burdens from cumulative debt paydown directly lift bottom-line net profit margins.
Q3 2029	32.01	+2.47%	+15.74%	Global commercial oncology sales achieve blockbuster velocity, demonstrating sustained pricing power across hospital channels. Robust operational cash conversion comfortably covers capital commitments, reinforcing corporate credit standing.
Q4 2029	32.85	+2.63%	+18.78%	Cumulative enterprise restructuring reaches targeted run-rate savings, establishing a leaner operational cost baseline. Year-end institutional allocations reward predictable healthcare dividend yields amid late-cycle macroeconomic deceleration.
Q1 2030	33.68	+2.50%	+21.75%	Commercial launch preparations for acquired metabolic therapies and expanded biologic indications trigger sell-side earnings upgrades. Operating margins stabilize firmly in the upper twenties following multi-year infrastructure rationalization.
Q2 2030	34.42	+2.20%	+24.43%	Initial commercial uptake of newly approved therapies demonstrates expanding volume in chronic maintenance settings. Steady cash flows accelerate balance-sheet de-risking, lowering enterprise-wide financial leverage ratios.
Q3 2030	35.24	+2.38%	+27.39%	Expanding international adoption for specialized antibody-drug conjugates solidifies therapeutic leadership. Rising returns on invested capital prompt equity analysts to adjust forward terminal valuation multiples upward.
Q4 2030	36.03	+2.24%	+30.24%	Operational results highlight sustained revenue recovery, with organic biopharma growth fully compensating for past patent losses. Enhanced balance-sheet flexibility allows management to evaluate renewed share repurchases alongside distributions.
Q1 2031	36.85	+2.30%	+33.24%	Commercial execution across oncology and cardiometabolic divisions delivers consistent quarterly earnings beats. Normalized operating margins extinguish historical market skepticism, driving steady capital accumulation among diversified funds.
Q2 2031	37.46	+1.64%	+35.42%	High-margin specialty biologic franchises insulate enterprise cash generation from residual small-molecule generic commoditization. Reliable free cash flow conversion comfortably funds ongoing clinical reinvestment and shareholder payouts.
Q3 2031	38.23	+2.06%	+38.21%	The five-year transition concludes with modernized clinical pipelines establishing durable proprietary market exclusivity. Terminal valuation multiples reach equilibrium, rewarding long-term capital with substantial intrinsic value realization.

The central investment debate hinges on an operational sequencing mismatch: approximately seventeen billion dollars in mature revenues face statutory patent expiries and Medicare pricing concessions through 2028, while acquired oncology pipelines and metabolic candidates mature on a delayed timeline. The market excessively discounts this valley by extrapolating top-line erosion into permanent capital destruction, pricing shares at a single-digit forward adjusted earnings multiple. In reality, ten billion dollars in enterprise-wide restructuring, the sunset of legacy tax obligations, and mid-teens operational growth in commercialized biologics establish a durable free cash flow floor near eleven billion dollars, insulating corporate liquidity. The strongest counterargument emphasizes capital allocation fragility under elevated interest rates. Gross debt exceeding sixty billion dollars combines with a rigid nine-point-eight-billion-dollar dividend commitment, leaving minimal cushion for clinical trial failures or aggressive biosimilar pricing erosion.

Key insights

Sustained free cash flow yield near seven percent establishes an asymmetric margin of safety against small-molecule generic commoditization.
Acquired antibody-drug conjugate scaling structurally shifts enterprise gross margins above seventy percent, replacing decaying chemical revenues with high-barrier biologic pricing.
Balance-sheet de-risking remains the gating factor for multiple expansion, as debt amortization takes strict precedence over opportunistic share buybacks.

Deep Dive

Prevailing market consensus treats the equity as an uninvestable value trap caught in an irreversible post-pandemic hangover. Investors assume an impending seventeen-billion-dollar patent cliff will crush operating income while sixty billion dollars in acquisition debt and an unyielding dividend exhaust liquidity. The crowd anchors on recent clinical write-downs, pricing in perpetual structural decline and viewing the high yield as an impending dividend cut.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates fundamental value by misinterpreting temporary GAAP impairments as permanent operational cash erosion. The analytical edge rests on recognizing that non-COVID commercial revenues are expanding at mid-single digits, supported by high-margin oncology biologics and multi-billion-dollar cost-realignment programs. Crucially, the final repatriation-tax payment removes an ongoing cash drain. This cash-generation floor protects dividend coverage and debt servicing, refuting the market's linear extrapolation of financial decay.

Repricing catalyst

Market repricing will trigger as consecutive reporting cycles through late 2027 demonstrate that realized cost savings and commercial oncology expansion keep trailing free cash flow safely above dividend commitments despite initial Medicare price concessions. Pivotal Phase 3 clinical readouts for monthly metabolic maintenance candidates will further dismantle the structural decline thesis, forcing sell-side analysts to revise depressed terminal cash-flow multiples upward.

Published consensus context

Macro regime alignment

The prevailing monetary regime of restrictive policy rates near four percent and elevated sovereign yields creates refinancing friction for the company's sixty-billion-dollar debt burden. However, non-cyclical pharmaceutical demand provides robust pricing insulation against broader economic deceleration, making the defensive six-percent cash distribution an attractive haven during macroeconomic volatility.

Published consensus context

Advisor disagreement

The decisive analytical dispute centers on cash-flow durability versus patent-cliff velocity through 2028. Bullish perspectives argue that eleven billion dollars in recurring free cash flow, supported by structural cost cuts and oncology growth, easily bridges the transition until metabolic pipelines commercialize. Conversely, bearish models assert that rapid generic erosion across cardiovascular lines will overwhelm operational savings, leaving free cash flow insufficient to cover both debt service and nearly ten billion dollars in annual dividends. Monitoring quarterly non-COVID commercial revenue growth against free cash flow dividend coverage through 2027 will definitively resolve this debate.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Commercial antibody conjugate oncology scaling: Integration of acquired antibody-drug conjugates establishes a dominant specialty oncology infrastructure led by Padcev and Adcetris expanding into first-line indications. This biologics portfolio commands durable patent exclusivity extending well into the 2030s. Generating double-digit volume expansion across global cancer centers, this franchise expands gross margins and directly replaces maturing small-molecule revenue streams. Expected impact: +20%.
Enterprise manufacturing and operational restructuring: Management is methodically executing cumulative multi-year net cost reductions exceeding seven billion dollars across administrative, research, and manufacturing nodes. Streamlining post-pandemic operating footprints permanently lowers enterprise break-even thresholds. This expenditure discipline insulates operating margins above twenty-five percent, preserving recurring cash generation to fully defend dividend commitments through the patent expiration transition. Expected impact: +16%.
Non-COVID commercial portfolio volume expansion: Underlying commercial therapies demonstrate consistent four-to-seven percent operational volume growth, driven by specialty cardiovascular, migraine, and pneumococcal vaccine lines. Aging global demographics sustain non-cyclical institutional prescription demand, decoupling fundamental product consumption from broader macroeconomic turbulence and providing a reliable revenue baseline of approximately sixty billion dollars annually. Expected impact: +12%.
Legacy cash tax obligation sunset: The conclusion of multi-year repatriation tax installments removes a substantial annual cash obligation from the balance sheet starting in 2027. This regulatory sunset directly enhances recurring free cash flow retention without altering reported GAAP operating income, widening the safety buffer for dividend distributions and accelerating post-acquisition debt amortization. Expected impact: +10%.

Top frictions and headwinds

Multi-blockbuster patent cliff revenue chasm: Impending loss of exclusivity across core revenue pillars between 2026 and 2028 exposes approximately seventeen billion dollars in high-margin sales to generic competition. Rapid erosion across Eliquis, Ibrance, and Xtandi eliminates substantial operating profit. This structural headwind depresses top-line growth, requiring aggressive pipeline commercialization simply to maintain stable enterprise earning power. Expected impact: -20%.
Statutory Medicare price negotiation compression: Mandatory drug price setting under the Inflation Reduction Act imposes statutory discounts on key commercial medicines, led by Eliquis starting in 2026. Administrative price ceilings compress gross margins across Medicare Part D populations, permanently curtailing historical pharmaceutical pricing flexibility and accelerating cash-flow deterioration ahead of formal generic entry. Expected impact: -11%.
Debt refinancing friction under tight policy: Funded debt exceeding sixty billion dollars following major acquisitions faces elevated refinancing rates under restrictive central bank policies. Higher debt-service carrying costs consume critical cash flow, depressing net earnings recovery and severely restricting capital allocation flexibility for discretionary share repurchases or additional bolt-on business development. Expected impact: -10%.
Pipeline reinvestment burden and late attrition: Replacing exhausted blockbusters requires expending nearly twelve billion dollars annually in clinical research amidst inherent biological attrition risks. High-profile trial failures, such as recent non-cash asset impairments, destroy invested capital and delay commercial replacement timelines, reinforcing market skepticism regarding internal research and development productivity. Expected impact: -8%.

Tail risks

Forced dividend reduction under cash strain: Should patent erosion outpace pipeline commercialization while elevated interest expenses squeeze free cash flow below eight billion dollars, the board could be forced to reduce the dividend payout. Cutting distributions would trigger widespread institutional income-fund liquidation, causing an immediate, severe derating of equity multiples toward tangible book value. Probability: +24%. Expected impact: -28%.
Late-stage oncology trial confirmatory failures: Pivotal Phase 3 confirmatory trials for core acquired antibody-drug conjugates could miss overall survival endpoints or exhibit unexpected toxicities by 2028. Such setbacks would force massive non-cash goodwill impairments, dismantle the primary post-cliff replacement narrative, and permanently depress terminal valuation multiples across institutional research. Probability: +22%. Expected impact: -24%.

Tail opportunities

Monthly metabolic maintenance clinical breakthrough: Pivotal Phase 3 trials could establish acquired metabolic candidate MET097 or berobenatide as a premier once-monthly obesity maintenance therapy by 2028. Demonstrating competitive weight loss with superior patient persistence would capture significant share in a hundred-billion-dollar market, injecting multi-billion-dollar peak sales that completely overcome patent cliff drag. Probability: +32%. Expected impact: +32%.
Accelerated pan-tumor oncology label expansions: Key antibody-drug conjugates could secure expedited regulatory approvals across broader first-line indications in lung, breast, and solid tumors by late 2027. Unlocking large patient cohorts ahead of schedule would accelerate commercial oncology revenues past fifteen billion dollars annually, catalyzing immediate multiple expansion across institutional models. Probability: +30%. Expected impact: +24%.

What to monitor

Thesis watchpoints

-- Trailing free cash flow maintaining above ten billion dollars through 2027 confirms dividend safety and operational stability.

Key insights

Non-COVID commercial revenue growth falling below four percent across 2027 signals that generic erosion is overwhelming operational savings.
Discontinuation of pivotal Phase 3 metabolic trials before 2028 requires an immediate downward reassessment of long-term commercial replenishment.

Company Financial Analysis

Pfizer Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Pfizer's financial story is one of operational stabilization following the post-pandemic vaccine unwind. Headline revenue stabilized near sixty-three point seven billion dollars for the trailing twelve months through mid-2026, demonstrating that non-COVID medicines are growing steadily. Although accounting results showed a net loss in the second quarter of 2026 due to a four-point-three-billion-dollar non-cash clinical trial impairment, core operating income remained resilient at nearly sixteen billion dollars. This gap reveals that actual cash generation is significantly healthier than reported net losses suggest. Trailing free cash flow reached eleven billion dollars, providing crucial liquidity to self-fund operations and protect shareholder distributions as legacy patent expirations approach.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 62.6B	USD 7.8B	USD 9.1B
2024	USD 63.6B	USD 8B	USD 9.8B
2023	USD 59.6B	USD 2.1B	USD 4.8B
2022	USD 100.3B	USD 31.4B	USD 26B
2021	USD 81.3B	USD 22.1B	USD 29.9B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	18.2x	TTM	Native	USD / USD
2024	18.9x	TTM	Native	USD / USD
2023	76.3x	TTM	Native	USD / USD
2022	9.4x	Annual	Native	USD / USD
2021	15.4x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profitability is rebounding after absorbing pandemic-related disruptions. Gross margins expanded to seventy point three percent in fiscal 2025, recovering from fifty point nine percent in 2023 as low-margin vaccine inventories cleared and sales shifted toward high-margin cancer biologics. Operating margins stabilized near twenty-five percent, directly supported by ongoing corporate cost-reduction programs. This margin pattern demonstrates underlying pricing power across specialized treatments. Enterprise restructuring initiatives targeting billions in cumulative operational savings provide vital operating leverage. This disciplined cost containment creates a durable cushion that protects profitability even as mature small-molecule drugs encounter generic price competition.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 15.4B	24.7%	12.4%
2024	USD 16.5B	25.9%	12.6%
2023	USD 5.3B	8.9%	3.6%
2022	USD 37.5B	37.4%	31.3%
2021	USD 20.8B	25.6%	27.2%

Balance sheet and leverage

AI Review

The balance sheet carries substantial obligations from past debt-financed acquisitions, with funded debt standing near sixty billion dollars against eighty-six point five billion dollars in equity. This leverage results in a debt-to-equity ratio of zero point seven eight and interest coverage near three point eight times in fiscal 2025. While manageable, this debt burden limits discretionary share buybacks. Crucially, solvency remains safeguarded by strong liquidity and healthy operational cash flow. Well-staggered debt maturities prevent immediate refinancing crises, though paying nearly ten billion dollars in annual dividends consumes most available cash. Management must maintain disciplined debt repayment to preserve investment-grade credit ratings.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 67.4B	USD 13.6B	USD 66.3B net debt	1.16x
2024	USD 67B	USD 20.5B	USD 66B net debt	1.17x
2023	USD 75B	USD 12.7B	USD 72.2B net debt	0.91x
2022	USD 35.8B	USD 22.7B	USD 34.5B net debt	1.22x
2021	USD 38.4B	USD 31.1B	USD 35.1B net debt	1.40x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management has exercised strict capital discipline by curtailing physical construction and factory expansions. Capital expenditures consumed roughly four point two percent of revenues in 2025, freeing up valuable cash to defend the balance sheet. Instead, financial firepower is concentrated directly in research laboratories, where nearly twelve billion dollars was committed to research and development in 2025. This spending profile demonstrates a clear corporate choice: avoid sinking money into unnecessary physical infrastructure while aggressively funding high-yield clinical trials. By prioritizing advanced cancer therapies and metabolic drug candidates, management aims to ensure pipeline renewals replace expiring revenues without requiring dilutive external financing.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 2.6B	USD 12B
2024	USD 2.9B	USD 10.7B
2023	USD 3.9B	USD 10.6B
2022	USD 3.2B	USD 11.4B
2021	USD 2.7B	USD 13.8B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	BUY	146	+10.6%	Not available	ORIGINAL
5Y	BUY	195	+72.8%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	26.83	28.13	28.49	14
+6M	March 18, 2027	26.84	28.58	29.63	14
+9M	June 18, 2027	25.49	28.89	30.22	14
+1Y	September 18, 2027	24.47	29.4	31.43	14
+15M	December 18, 2027	23.74	29.46	31.75	14
+18M	March 18, 2028	22.32	29.31	32.7	14
+21M	June 18, 2028	20.31	29.04	32.04	14
+2Y	September 18, 2028	19.49	29.62	33	14
+27M	December 18, 2028	19.88	30.41	33.66	14
+30M	March 18, 2029	20.48	31.23	34.67	14
+33M	June 18, 2029	21.3	32.04	36.05	14
+3Y	September 18, 2029	21.94	32.82	37.13	14
+39M	December 18, 2029	22.82	33.66	38.61	14
+42M	March 18, 2030	23.5	34.52	39.39	14
+45M	June 18, 2030	24.21	35.28	41.36	14
+4Y	September 18, 2030	24.93	36.12	42.6	14
+51M	December 18, 2030	25.43	36.96	44.3	14
+54M	March 18, 2031	26.19	37.8	45.19	14
+57M	June 18, 2031	26.72	38.47	46.99	14
+5Y	September 18, 2031	27.25	39.25	48.4	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

The Whistleblower

The Value Seeker

Gemini 3.8 Flash

Weight0.0/100

Zero weight is assigned due to substantial analytical correlation with preceding value frameworks, alongside an unverified claim that pending Depo-Provera multidistrict litigation presents a base-case five-billion-dollar cash drain within the primary forecast window.

Skip to references

Research Provenance

References & Context

This Pfizer consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 118 deduplicated sources retained for this batch.

01Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 | CMScms.gov
02Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
03https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm?utm_source=openaisec.gov
04pfe-20260628sec.gov
05PFIZER INC - Form 8-K - FY2026sec.gov
06PFIZER INC - Form 8-K - FY2026sec.gov
07Press Releasewelch.senate.gov
08Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White Housewhitehouse.gov
09Fact Sheet: President Donald J. Trump Announces Deal with Regeneron to Bring Most-Favored-Nation Pricing to American Patients – The White Housewhitehouse.gov
10Pfizer's 6% Yield Masks a Fragile Dividend Story - 24/7 Wall St.247wallst.com
11Trump faces new pressure over his "most favored nation" drug pricing dealsaxios.com
12Pfizer Announces Chief Financial Officer Transitionbusinesswire.com
13Pfizer’s obesity bet shows 14.1% weight loss in Phase IIb trialclinicaltrialsarena.com
14Pfizer (PFE) earnings Q2 2026cnbc.com
15Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2bfiercebiotech.com

And 103 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.